Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | IGF1R | P08069 | 9/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | PAK4 | O96013 | 2/20 | 0.42 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29592850 | 0.97 | NEK1 (0.48) | NEK1SRCIGF1RCCNE1CDK2 | |
| SCHEMBL24065077 | 0.97 | NEK1 (0.48) | NEK1SRCIGF1RCCNE1CDK2 | |
| SCHEMBL24065149 | 0.85 | IGF1R (0.44) | NEK1SRCIGF1RPAK4PAK1 | |
| SCHEMBL24065039 | 0.85 | PAK4 (0.59) | NEK1ALDH1A1RAB9ASRCIGF1R | |
| SCHEMBL24065031 | 0.85 | PAK4 (0.59) | NEK1ALDH1A1RAB9ASRCIGF1R | |
| SCHEMBL24065151 | 0.85 | SRC (0.50) | NEK1SRCIGF1RPAK4PAK1 | |
| SCHEMBL25292486 | 0.84 | IGF1R (0.45) | NEK1SRCIGF1RCCNE1CDK2 | |
| SCHEMBL29594362 | 0.84 | IGF1R (0.45) | NEK1SRCIGF1RCCNE1CDK2 | |
| SCHEMBL25243495 | 0.82 | IGF1R (0.43) | NEK1SRCIGF1RPAK4PAK1 | |
| SCHEMBL29592939 | 0.82 | IGF1R (0.43) | NEK1SRCIGF1RPAK4PAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210369710-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2021-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210369710-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | MYC, MYCBP, MYCBP2 | NEK1 890/4885ALDH1A1 4067/4885RAB9A 1219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.